• United States
  • Canada
  • Mexico
  • China
  • Middle East
  • Japan
  • Europe
  • Sales
  • Marketing
emphycorp logo
emphycorp logo
  • About Us
    • About Us
    • Management and Advisors
    • OUR MEDICAL STUDIES
  • Our Drug Pipeline
    • Our Drug Pipeline
    • PULMONARY FIBROSIS TREATMENT®
    • COVID-19 TREATMENT®
    • COVID-19 LONG HAULERS TREATMENT®
    • FLU TREATMENT®
    • UNMET NEEDS BREATHING TREATMENT®
    • NON-STEROIDAL COPD NASAL SPRAY®
    • 70% LOWER STEROID COPD®
    • NON-STEROIDAL ALZHEIMER’S NASAL SPRAY®
    • CONCUSSIONS TREATMENT®
    • DRUG FREE CANCER PRE-TREATMENT®
    • SMOKING CESSATION ORAL SPRAY®
  • Conditions We Can Treat
    • HYPOXEMIA
    • PULMONARY FIBROSIS
    • COVID-19
    • COVID LONG HAULERS
    • FLU
    • ASTHMA
    • COPD
    • EMPHYSEMA
    • SARCOIDOSIS
    • CYSTIC FIBROSIS (CF)
    • CHRONIC BRONCHITIS
    • INTERSTITIAL LUNG DISEASE
    • VIRAL and BACTERIAL Infections
  • FDA Submissions
    • REGULATION OF NITRIC OXIDE
    • SODIUM PYRUVATE
    • N115 FDA SUBMISSIONS
  • Contact Us
    • Investor Relations
    • Partnerships
  • News/Press/Blog
    • Emphycorp News & Peer Reviewed Articles
    • PRESS RELEASES
    • Blog
    • NEW PULMONARY FIBROSIS TREATMENT
  • United States
  • Canada
  • Mexico
  • China
  • Middle East
  • Japan
  • Europe
  • Sales
  • Marketing
Press Releases

Non-Steroidal Nasal Sprays with no adverse effects for Treatment of Respiratory Diseases, COVID-19, Long COVID, Flu, and more.

Press Releases
  1. Home
  2. Features
  3. Press Releases

 

PRESS RELEASES

To read and or download the pdf articles click on the links below.

 

  • pdf iconOctober 5, 2021 – EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (Long Haulers), and Pulmonary Fibrosis

  • pdf iconDecember 1 2020 – Sodium Pyruvate Ameliorates Influenza A Virus Infection In Vivo _ Peer Review bioRxiv

  • pdf iconApril 7, 2020  – EmphyCorp N115 News: Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide

  • pdf iconMarch 24, 2020 – EmphyCorp News: As Reported in The Lancet – Clinical Features of Patients Infected with the 2019 novel Coronavirus in Wuhan, China

  • pdf iconMarch 17, 2020  – EmphyCorp News: Nitric Oxide is currently being tested in Clinical Trials as a Potential Treatment for Patients infected with the Coronavirus

  • pdf iconJanuary 21, 2020 – EmphyCorp N115 Rx Globally Patented Non-Steroidal Nasal Spray with No Known Side Effects for Pregnant Women with Allergic Rhinitis or Asthma

  • pdf iconJanuary 14, 2020 – Rx Globally Patented Non-Steroidal Nasal Spray for All Lung Diseases including Pulmonary Fibrosis, CF, COPD, Unmet Needs with No Known Side Effects that can also be used to Deliver Antivirals, Antimicrobials, Insulin, and other Drugs

  • pdf iconAugust 15, 2019 – EmphyCorp Inc. FDA Submission for Rx New Non-Steroidal Nasal Spray for Pulmonary Fibrosis w/ No Known Side Effects
emphycorp logo white

Terms and Conditions

Focus Pages

  • About Emphycorp
 
  • Emphycorp News
 
  • Investor Relations

Address

84 Park Avenue, Suite E-102
Flemington, New Jersey
08822 USA

Start a conversation

SALES: (973) 586-4421
MARKETING: (973) 586-4421

© 2023 Emphycorp Inc. . All rights reserved

Privacy Preference Center

Privacy Preferences